RRC ID 69710
Author Yamali C, Gul HI, Ece A, Bua S, Angeli A, Sakagami H, Sahin E, Supuran CT.
Title Synthesis, biological evaluation and in silico modelling studies of 1,3,5-trisubstituted pyrazoles carrying benzenesulfonamide as potential anticancer agents and selective cancer-associated hCA IX isoenzyme inhibitors.
Journal Bioorg Chem
Abstract Inhibition of carbonic anhydrases (CAs, EC has clinical importance for the treatment of several diseases. They participate in crucial regulatory mechanisms for balancing intracellular and extracellular pH of the cells. Among CA isoforms, selective inhibition of hCA IX has been linked to decreasing of cell growth for both primary tumors and metastases. The discovery of novel CA inhibitors as anticancer drug candidates is a current topic in medicinal chemistry. 1,3,5-Trisubstituted pyrazoles carrying benzenesulfonamide were evaluated against physiologically abundant cytosolic hCA I and hCA II and trans-membrane, tumor-associated hCA IX isoforms by a stopped-flow CO2 hydrase method. Their in vitro cytotoxicities were screened against human oral squamous cell carcinoma (OSCC) cell lines (HSC-2) and human mesenchymal normal oral cells (HGF) via 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) test. Compounds 6, 8, 9, 11, and 12 showed low nanomolar hCA II inhibitory potency with Ki < 10 nM, whereas compounds 9 and 12 displayed Ki < 10 nM against hCA IX isoenzyme when compared with reference Acetazolamide (AZA). Compound 9, 4-(3-(hydrazinecarbonyl)-5-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide, can be considered as the most selective hCA IX inhibitor over off-target cytosolic isoenzymes hCA I and hCA II with the lowest Ki value of 2.3 nM and selectivity ratios of 3217 (hCA I/hCA IX) and 3.9 (hCA II/hCA IX). Isoform selectivity profiles were also discussed using in silico modelling. Cytotoxicity results pointed out that compounds 5 (CC50 = 37.7 μM) and 11 (CC50 = 58.1 μM) can be considered as lead cytotoxic compounds since they were more cytotoxic than 5-Fluorouracil (5-FU) and Methotrexate (MTX).
Volume 92
Pages 103222
Published 2019-11-1
DOI 10.1016/j.bioorg.2019.103222
PII S0045-2068(19)30693-5
PMID 31499260
MeSH Antineoplastic Agents / chemical synthesis Antineoplastic Agents / chemistry Antineoplastic Agents / pharmacology* Carbonic Anhydrase IX / antagonists & inhibitors* Carbonic Anhydrase IX / metabolism Carbonic Anhydrase Inhibitors / chemical synthesis Carbonic Anhydrase Inhibitors / chemistry Carbonic Anhydrase Inhibitors / pharmacology* Cell Proliferation / drug effects Cells, Cultured Child Dose-Response Relationship, Drug Drug Screening Assays, Antitumor Female Humans Isoenzymes / antagonists & inhibitors Isoenzymes / metabolism Models, Molecular Molecular Structure Pyrazoles / chemical synthesis Pyrazoles / chemistry Pyrazoles / pharmacology* Structure-Activity Relationship Sulfonamides / chemistry Sulfonamides / pharmacology*
IF 4.831
Human and Animal Cells HSC-2(RCB1945)